CClinicalTrials.gg
Status unknownNCT04178876CLESSUpdated Dec 4, 2019

Comparison of Laparoscopic Endometrioma Stripping Versus Ethanol Sclerotherapy( CLESS)

An interventional study of ethanol sclerotherapy and stripping technique in Endometrioma, sponsored by Catholic University of the Sacred Heart. Status unknown at 1 site in Italy. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2019-12-04.

Sponsored by Catholic University of the Sacred Heart · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The aim of this study is to compare two different laparoscopic surgical techniques (endometrioma stripping vs ethanol sclerotherapy) in terms of ovarian reserve (AMH levels), recurrence rate and pain relief.

Read the detailed description

Patients with pelvic pain (VAS score≥4) and ultrasound diagnosis of endometrioma > 4cm candidate to surgical removal of endometrioma will be randomized into 2 group. One Group will undergo laparoscopical stripping technique; the other one will undergo laparoscopic aspiration and sclerotherapy using 95% ethanol.

The women will be introduced with both operative options and they will be informed about the randomization . After an elaborate explanation about the study they will sign an informed consent form. the following data will be collected prior the operation: age, gravity \& parity, operative history, general medical history, the cyst size, AMH (Anti Mullerian Hormone), symptoms related to endometriosis (through VAS score), fertility history including any fertility treatment in the past and planned pregnancy after the operation.

The laparoscopy will take place in Fondazione Policlinico Gemelli IRCSS, Roma. in the study group the cyst content will be aspirated and flushed with normal saline. 95% sterile ethanol will be instilled into the cyst through a Nelathon catheter. Ethanol will be left in the cyst for 15 min then aspirated as completely as possible following normal saline flushing. In the control group we will follow the standard treatment which is cystectomy.

The women will be followed at 1 , 3 , 6 and 12 months after the surgery.

02

Conditions studied

  • Endometrioma

Browse trials for

Keywords

  • endometrioma
  • ethanol
  • sclerotherapy
  • aspiration
  • ovarian reserve
  • endometriosis
  • AMH
03

In context

Endometriosis

901 studies on the registry are indexed under Endometriosis; 259 are open to participants now.

This study's planned enrollment of 64 is close to the median of 64 across 525 interventional studies indexed under Endometriosis.

Browse Endometriosis studies →

Lead sponsor

Catholic University of the Sacred Heart is the lead sponsor of 227 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Women between 18-35 years old
  • Women with ultrasound diagnosis of ovarian endometrioma ≥4cm (with or without deep infiltrating endometriosis)
  • History of dysmenorrhea and/or chronic pelvic pain
  • candidates for elective laparoscopy due to endometriosis.

Exclusion criteria

Exclusion Criteria:

    • Previous surgery for ovarian endometriosis
  • Evidence of premature ovarian failure (follicle stimulating hormone ≥40 international units/L)
  • Endocrinal disorders that might affect ovarian function (e.g., polycystic ovary syndrome, thyroid dysfunction, hyperprolactinemia)
  • Ultrasound suspicious of ovarian malignant disease according IOTA criteria
  • endometrial cyst \< 4 cm. • ethanol sensitivity.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Aspiration and Sclerotherapy of endometriomas

    Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas

    Procedure: ethanol sclerotherapy

  • Active comparator
    laparoscopic stripping technique

    cystectomy of endometriomas during laparoscopy

    Procedure: stripping technique

Interventions

  • Procedureethanol sclerotherapy

    Endometrioma laparoscopic aspiration and sclerotherapy using 95% ethanol

  • Procedurestripping technique

    Endometrioma laparoscopic cystectomy

06

What researchers measure

Primary outcomes

  1. impact on ovarian reserve, in terms of reduction of serum AMH levels

    The AMH levels will be evaluated 1 month before the surgery and 1, 6 and 12 months after surgery.

    Time frame: up to 12 months after the laparoscopy

Secondary outcomes

  1. endometrioma recurrence rate for the two surgical techniques

    Ultrasound examination that demonstrate the presence/lack of ovarian cyst with sonographic features of endometrioma in the ovary where the procedure took place.

    Time frame: up to 12 months after the laparoscopy

  2. pain relief after surgery

    The severity of pelvic pain , assessed using a visual analogue scale with no-pain classified as 0 and worst imaginable pain as 10.

    Time frame: up to 12 months after the laparoscopy

07

Study locations

1 of 1 sites recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    Roma, 00168, Italy
    Recruiting
08

References and documents

Publications

  • Sweed MS, Makled AK, El-Sayed MA, Shawky ME, Abd-Elhady HA, Mansour AM, Mohamed RM, Hemeda H, Nasr-Eldin EA, Attia NS, Eltaieb E, Allam H, Hussein A. Ovarian Reserve Following Laparoscopic Ovarian Cystectomy vs Cyst Deroofing for Endometriomas. J Minim Invasive Gynecol. 2019 Jul-Aug;26(5):877-882. doi: 10.1016/j.jmig.2018.06.022. Epub 2018 Sep 5. PubMed 30193971 ↗
  • Cohen A, Almog B, Tulandi T. Sclerotherapy in the management of ovarian endometrioma: systematic review and meta-analysis. Fertil Steril. 2017 Jul;108(1):117-124.e5. doi: 10.1016/j.fertnstert.2017.05.015. Epub 2017 Jun 1. PubMed 28579409 ↗
  • Messalli EM, Cobellis G, Pecori E, Pierno G, Scaffa C, Stradella L, Cobellis L. Alcohol sclerosis of endometriomas after ultrasound-guided aspiration. Minerva Ginecol. 2003 Aug;55(4):359-62. PubMed 14581861 ↗
  • Garcia-Tejedor A, Castellarnau M, Ponce J, Fernandez ME, Burdio F. Ethanol sclerotherapy of ovarian endometrioma: a safe and effective minimal invasive procedure. Preliminary results. Eur J Obstet Gynecol Reprod Biol. 2015 Apr;187:25-9. doi: 10.1016/j.ejogrb.2015.02.004. Epub 2015 Feb 16. PubMed 25739052 ↗
  • Kovacevic VM, Andelic LM, Mitrovic Jovanovic A. Changes in serum antimullerian hormone levels in patients 6 and 12 months after endometrioma stripping surgery. Fertil Steril. 2018 Nov;110(6):1173-1180. doi: 10.1016/j.fertnstert.2018.07.019. PubMed 30396562 ↗

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04178876
Lead sponsor
Catholic University of the Sacred Heart
Responsible party
Prof. Giovanni Scambia (Professor, Catholic University of the Sacred Heart) — Principal investigator
First posted
Nov 26, 2019
Start date
Sep 13, 2019
Primary completion
Nov 1, 2022 (estimated)
Completion
Jun 1, 2023 (estimated)
Last update
Dec 4, 2019

Study contacts

Alessandra De Cicco Nardone, MD
Contact
alessandradecicco@gmail.com
+393428235829
Giovanni Scambia, MD
principal investigator · Fondazione Policlinico Gemelli, IRCSS Università Cattolica del Sacro Cuore, Roma

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion